FTT Logo
Editorial standard: How we test and compare

Glucotrack plans US FDA trial for implantable continuous glucose monitor in 2026

Marty S.

·

·

NBC Select Announces 2026 Wellness Award Winners

📊 Industry Moves

Glucotrack’s implantable continuous glucose monitor measures blood instead of interstitial fluid—a real advantage over Dexcom G6 and FreeStyle Libre—but the 2027+ launch window and biocompatibility unknowns mean your current CGM won’t be obsolete anytime soon. If they pull it off, endurance athletes and metabolic biohackers get the accuracy upgrade they’ve been waiting for.

Source: MedTech Dive

wearables

More from Pulse

Clinicians call for better role in wearable device development to align with real-world care delivery
Apr 9
FDA issues revised guidance limiting oversight of AI health software and wearables
Mar 31
Amazfit Balance 2 Gets Major Update: New BioCharge Features and Bug Fixes
Apr 15

Marty S.

Marty is a contributor at Fitness Tech Trends, focused on helping readers cut through the noise and make informed decisions about fitness technology. He dives deep into product comparisons, analyzes features that actually matter, and breaks down technical specs into practical insights. Whether readers are choosing between heart rate monitors, deciding on recovery tools, or figuring out which smartwatch fits their training style, Marty aims to provide straightforward, no-hype guidance. When he’s not researching the latest gear, he’s probably testing theories about what makes certain products stick while others fade into the gadget graveyard.